Stock Events

Stock Events

IRulya Therapeutics 

$27.65
0
-$4.84-14.9% 15:51 Today

Statistics

Day High
30.8
Day Low
25.5
52W High
910
52W Low
15.1
Volume
57,542
Avg. Volume
30,984
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IRLA. It's not an investment recommendation.
Microsoft
9
MSFT
Apple
8
AAPL
Amazon
8
AMZN
Tesla
8
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.36B
CRISPR Therapeutics AG focuses on the development of gene-based medicines, including therapies for genetic diseases, competing in the same innovative healthcare space as Quince.
Editas Medicine
EDIT
Mkt Cap402.38M
Editas Medicine, Inc. works on editing genes to treat genetic diseases, directly competing with Quince's approach to addressing genetic disorders.
Intellia Therapeutics
NTLA
Mkt Cap1.72B
Intellia Therapeutics, Inc. is a leading developer of CRISPR/Cas9 gene-editing therapies for genetic diseases, making it a direct competitor in the genetic medicine field.
Voyager Therapeutics
VYGR
Mkt Cap150.96M
Voyager Therapeutics, Inc. specializes in the development of gene therapies for neurodegenerative diseases, competing in the broader market of genetic disorder treatments.
Protagonist Therapeutics
PTGX
Mkt Cap9.06B
Protagonist Therapeutics, Inc. is engaged in the discovery and development of novel peptide-based drugs, which could compete with Quince's therapeutic approaches in a broader sense.
Fate Therapeutics
FATE
Mkt Cap277.98M
Fate Therapeutics, Inc. is involved in the development of programmed cellular immunotherapies for cancer and immune disorders, competing in the innovative treatment space.
Regenxbio
RGNX
Mkt Cap490.48M
REGENXBIO Inc. focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy, which competes with Quince's focus on regenerative medicine and genetic therapies.

About

Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Show More
CEO
Dirk Thye
Employees
38
Country
United States
ISIN
US22053A3059

Listings

XNAS
US
IRLA
XNAS
US
QNCX
BOATS
BOATS
QNCX.BOATS

0 Comments

Share your thoughts

FAQs

What is IRulya Therapeutics stock price today?▼
The current price of IRLA is $27.65 USD — it has decreased by -14.9% in the past 24 hours. Watch IRulya Therapeutics stock price performance more closely on the chart.
What is IRulya Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange IRulya Therapeutics stocks are traded under the ticker IRLA.
How many employees does IRulya Therapeutics have?▼
As of October 13, 2026, the company has 38 employees.
In which sector is IRulya Therapeutics located?▼
IRulya Therapeutics operates in the Health & Wellness sector.
When did IRulya Therapeutics complete a stock split?▼
IRulya Therapeutics has not had any recent stock splits.
Where is IRulya Therapeutics headquartered?▼
IRulya Therapeutics is headquartered in SOUTH SAN FRANCISCO, United States.